What is HC Wainwright’s Forecast for Geron FY2026 Earnings?

Geron Corporation (NASDAQ:GERN) – Analysts at HC Wainwright cut their FY2026 earnings per share estimates for Geron in a note issued to investors on Wednesday, August 5th. HC Wainwright analyst E. Bodnar now anticipates that the biopharmaceutical company will post earnings of ($0.05) per share for the year, down from their previous estimate of ($0.02). The consensus estimate for Geron’s current full-year earnings is ($0.02) per share.

Separately, Weiss Ratings lowered Geron from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 24th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $4.00.

Geron Price Performance

Shares of NASDAQ GERN opened at $1.57 on Friday. The business has a fifty day moving average price of $1.34 and a two-hundred day moving average price of $1.46. The stock has a market capitalization of $1.01 billion, a PE ratio of -14.27 and a beta of 0.61. The company has a debt-to-equity ratio of 0.52, a current ratio of 6.78 and a quick ratio of 4.96. Geron has a fifty-two week low of $1.04 and a fifty-two week high of $2.01.

Geron (NASDAQ:GERN) last posted its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Geron had a negative return on equity of 24.06% and a negative net margin of 34.17%.The company had revenue of $57.48 million for the quarter, compared to the consensus estimate of $55.30 million.

Institutional Trading of Geron

Several large investors have recently made changes to their positions in the company. 55 North Private Wealth LLC bought a new position in Geron in the fourth quarter valued at approximately $29,000. LCM Capital Management Inc raised its position in Geron by 80.6% during the fourth quarter. LCM Capital Management Inc now owns 22,400 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 10,000 shares in the last quarter. Vistica Wealth Advisors LLC bought a new stake in Geron during the fourth quarter worth $33,000. Hsbc Holdings PLC bought a new stake in Geron during the first quarter worth $33,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Geron by 3,307.6% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 25,148 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 24,410 shares in the last quarter. Institutional investors and hedge funds own 73.71% of the company’s stock.

Trending Headlines about Geron

Here are the key news stories impacting Geron this week:

• Positive Sentiment: RYTELO (imetelstat) net product revenue reached a record $57.5 million, up 11% sequentially and above analyst expectations of $55.3 million. The company reiterated its 2026 RYTELO revenue outlook of $220 million to $240 million. Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights
• Positive Sentiment: Geron ended the quarter with $327 million in cash, restricted cash and marketable securities, supporting continued commercialization of RYTELO and development activities. Management also appointed Chinmaya Rath as chief business officer. Company Results and Business Highlights
• Positive Sentiment: Call-option activity surged, with investors buying 10,326 calls—about 14 times the average volume—indicating heightened speculative interest and potentially bullish positioning.
• Neutral Sentiment: The earnings call focused on the RYTELO commercial launch, revenue growth and business execution. Geron Q2 2026 Earnings Call Transcript
• Negative Sentiment: Geron reported a quarterly loss of $0.02 per share, missing the consensus loss estimate of $0.01. The company continues to report negative profitability metrics, including a negative net margin and return on equity. Geron Second-Quarter Earnings Report
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for 2027 through 2030: estimates fell to $0.02, $0.12, $0.32 and $0.55, respectively. The reductions imply slower expected earnings growth and likely weighed on the stock. Geron Analyst Estimates

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.